At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BGLC BioNexus Gene Lab Corp.
Trading 01-22 10:24:08 EST
3.12
-0.01
-0.32%
High3.12Low3.02Vol3.83K
Open3.02D1 Closing3.13Amplitude3.19%
Mkt Cap7.38MTradable Cap5.30MTotal Shares2.36M
T/O11.65KT/O Rate0.23%Tradable Shares1.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing
Reuters  ·  2025-12-24
BRIEF-BioNexus Gene Lab Corp - Matthew L. Barsing Appointed As Chairman Of Chemrex Board - SEC Filing
BioNexus Gene Lab Corp - Matthew L. Barsing Appointed as Chairman of Chemrex Board - SEC Filing
THOMSON REUTERS  ·  2025-12-24
BioNexus Gene Lab Corp - Matthew L. Barsing Appointed as Chairman of Chemrex Board - SEC Filing
Chemrex Board Reshuffled Amid Governance Review at BioNexus Gene Lab Corp
Reuters  ·  2025-12-24
Chemrex Board Reshuffled Amid Governance Review at BioNexus Gene Lab Corp
Correction: Blue Gold Sets $15 Million Gold Trading Facility
MT Newswires Live  ·  2025-12-03
Correction: Blue Gold Sets $15 Million Gold Trading Facility
Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform
Reuters  ·  2025-12-03
Bionexus Gene Lab Completes Strategic Investment In Fidelion Diagnostics Secures 15% Equity Stake In Global Ai-Oncology Platform
BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics
Reuters  ·  2025-12-03
BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for Vitaguard™
THOMSON REUTERS  ·  2025-12-03
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for Vitaguard™
BioNexus Gene Lab Corp - Enters $500 Mln Equity Purchase Agreement
THOMSON REUTERS  ·  2025-12-02
BioNexus Gene Lab Corp - Enters $500 Mln Equity Purchase Agreement
BioNexus Gene Lab Corp - May Issue Shares to ARC Group International Over 36 Months
THOMSON REUTERS  ·  2025-12-02
BioNexus Gene Lab Corp - May Issue Shares to ARC Group International Over 36 Months
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
GlobeNewswire  ·  2025-12-02
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion
Reuters  ·  2025-12-01
BRIEF-Bionexus Gene Lab Corp - To Pay $2 Million License Fee To Fidelion
BioNexus Gene Lab Corp - to Pay $2 Mln License Fee to Fidelion
THOMSON REUTERS  ·  2025-12-01
BioNexus Gene Lab Corp - to Pay $2 Mln License Fee to Fidelion
BioNexus Gene Lab Secures Exclusive Southeast Asia License for VitaGuard MRD Platform
Reuters  ·  2025-12-01
BioNexus Gene Lab Secures Exclusive Southeast Asia License for VitaGuard MRD Platform
Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Reuters  ·  2025-11-20
Bionexus Gene Lab Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
BioNexus Gene Lab Corp. Announces Date for Upcoming Annual Meeting of Stockholders
Reuters  ·  2025-11-15
BioNexus Gene Lab Corp. Announces Date for Upcoming Annual Meeting of Stockholders
BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics
Reuters  ·  2025-11-12
BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics
BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements
Reuters  ·  2025-11-12
BioNexus Gene Lab Signs Southeast Asia MRD Commercialization Agreements
BioNexus Gene Lab Corp: Completion Is Conditioned on an Ip License Agreement Granting Bglc Exclusive Commercialization Rights Across Asean
THOMSON REUTERS  ·  2025-11-12
BioNexus Gene Lab Corp: Completion Is Conditioned on an Ip License Agreement Granting Bglc Exclusive Commercialization Rights Across Asean
BioNexus Gene Lab Corp - to Receive 15% of Fidelion Shares; Fidelion Will Receive 19.9% of Bglc's Pre-Money Outstanding Shares
THOMSON REUTERS  ·  2025-11-12
BioNexus Gene Lab Corp - to Receive 15% of Fidelion Shares; Fidelion Will Receive 19.9% of Bglc's Pre-Money Outstanding Shares
BioNexus Gene Lab Corp. (Nasdaq: Bglc) Announces Strategic Agreements With Fidelion Diagnostics for Southeast Asia Mrd Commercialization
THOMSON REUTERS  ·  2025-11-12
BioNexus Gene Lab Corp. (Nasdaq: Bglc) Announces Strategic Agreements With Fidelion Diagnostics for Southeast Asia Mrd Commercialization

Introduction

Company Name.
BioNexus Gene Lab Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Issue price:
--